Premium
Severe autoimmune hepatitis in a chronic myeloid leukemia patient treated with interferon alpha and with complete genetic response
Author(s) -
Steegmann Juan Luis,
Requena María José,
GarcíaBuey María Luisa,
Granados Enrique,
Romero Rafael,
FernándezRañada Jose María,
Moreno Ricardo
Publication year - 1998
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/(sici)1096-8652(199809)59:1<95::aid-ajh19>3.0.co;2-0
Subject(s) - medicine , alpha interferon , autoimmune hepatitis , myeloid leukemia , immunology , interferon alfa , hepatitis , leukemia , interferon , complication , myeloid
A patient with chronic myeloid leukemia (CML) treated with interferon alpha (IFN alpha) and who developed autoimmune hepatitis (AIH) is described. The patient was treated with IFN alpha 2a, a complete cytogenetic response was achieved 5 months later, and this response has lasted now more than 7 years. Autoimmune hypothyroidism appeared at 18 months of treatment, and 1 year later severe type I autoimmune hepatitis developed. To our knowledge this is the first report of such complication in an IFN alpha‐treated CML patient. Am. J. Hematol. 59:95–97, 1998. © 1998 Wiley‐Liss, Inc.